Advertisement

Topics

Bristol-Myers Squibb (BMY) Raised to Strong-Buy at Vetr

21:57 EDT 15 Apr 2018 | Topix

The brokerage currently has a $64.33 price objective on the biopharmaceutical company's stock. Vetr 's price target suggests a potential upside of 9.68% from the stock's current price.

Original Article: Bristol-Myers Squibb (BMY) Raised to Strong-Buy at Vetr

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb (BMY) Raised to Strong-Buy at Vetr"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...